These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34797516)

  • 1. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Bots SJ; Parker CE; Brandse JF; Löwenberg M; Feagan BG; Sandborn WJ; Jairath V; D'Haens G; Vande Casteele N
    BioDrugs; 2021 Nov; 35(6):715-733. PubMed ID: 34797516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab for induction of remission in Crohn's disease.
    Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.
    Garcês S; Demengeot J; Benito-Garcia E
    Ann Rheum Dis; 2013 Dec; 72(12):1947-55. PubMed ID: 23223420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database.
    Helwig U; Kostev K; Schmidt C
    J Clin Gastroenterol; 2021 Jan; 55(1):e1-e7. PubMed ID: 32011403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
    Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
    Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
    Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.
    Sun X; Cui Z; Wang Q; Liu L; Ding X; Wang J; Cai X; Li B; Li X
    Autoimmun Rev; 2024 Apr; 23(4):103530. PubMed ID: 38499168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis.
    Taneja V; Anand RS; El-Dallal M; Dong J; Desai N; Taneja I; Feuerstein JD
    Inflamm Bowel Dis; 2024 Apr; 30(4):585-593. PubMed ID: 37300512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.
    Singh S; Garg SK; Pardi DS; Wang Z; Murad MH; Loftus EV
    Mayo Clin Proc; 2014 Dec; 89(12):1621-35. PubMed ID: 25441399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    BMJ Open; 2023 Oct; 13(10):e073071. PubMed ID: 37788929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis.
    Chen L; Xu CJ; Wu W; Ding BJ; Liu ZJ
    J Dig Dis; 2021 Jul; 22(7):408-418. PubMed ID: 34048629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.